1
|
Muhsin SA, Abdullah A, kobashigawa E, Al-Amidie M, Russell S, Zhang MZ, Zhang S, Almasri M. A microfluidic biosensor for the diagnosis of chronic wasting disease. MICROSYSTEMS & NANOENGINEERING 2023; 9:104. [PMID: 37609007 PMCID: PMC10440343 DOI: 10.1038/s41378-023-00569-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 06/01/2023] [Accepted: 06/21/2023] [Indexed: 08/24/2023]
Abstract
Cervids are affected by a neurologic disease that is always fatal to individuals and has population effects. This disease is called chronic wasting disease (CWD) and is caused by a misfolded prion protein. The disease is transmitted via contact with contaminated body fluids and tissue or exposure to the environment, such as drinking water or food. Current CWD diagnosis depends on ELISA screening of cervid lymph nodes and subsequent immunohistochemistry (IHC) confirmation of ELISA-positive results. The disease has proven to be difficult to control in part because of sensitivity and specificity issues with the current test regimen. We have investigated an accurate, rapid, and low-cost microfluidic microelectromechanical system (MEMS) biosensing device for the detection of CWD pathologic prions in retropharyngeal lymph nodes (RLNs), which is the current standard type of CWD diagnostic sample. The device consists of three novel regions for concentrating, trapping, and detecting the prion. The detection region includes an array of electrodes coated with a monoclonal antibody against pathologic prions. The experimental conditions were optimized using an engineered prion control antigen. Testing could be completed in less than 1 hour with high sensitivity and selectivity. The biosensor detected the engineered prion antigen at a 1:24 dilution, while ELISA detected the same antigen at a 1:8 dilution. The relative limit of detection (rLOD) of the biosensor was a 1:1000 dilution of a known strong positive RLN sample, whereas ELISA showed a rLOD of 1:100 dilution. Thus, the biosensor was 10 times more sensitive than ELISA, which is the currently approved CWD diagnostic test. The biosensor's specificity and selectivity were confirmed using known negative RPLN samples, a negative control antibody (monoclonal antibody against bovine coronavirus BCV), and two negative control antigens (bluetongue virus and Epizootic hemorrhagic disease virus). The biosensor's ability to detect pathogenic prions was verified by testing proteinase-digested positive RLN samples.
Collapse
Affiliation(s)
- Sura A. Muhsin
- University of Missouri–Columbia, Electrical Engineering and Computer Science, Columbia, MO USA
| | - Amjed Abdullah
- University of Missouri–Columbia, Electrical Engineering and Computer Science, Columbia, MO USA
| | - Estela kobashigawa
- University of Missouri–Columbia, College of Veterinary Medicine, Veterinary Medical Diagnostic Laboratory, Columbia, MO USA
| | - Muthana Al-Amidie
- University of Missouri–Columbia, Electrical Engineering and Computer Science, Columbia, MO USA
| | | | - Michael Z. Zhang
- University of Missouri–Columbia, College of Veterinary Medicine, Veterinary Medical Diagnostic Laboratory, Columbia, MO USA
| | - Shuping Zhang
- University of Missouri–Columbia, College of Veterinary Medicine, Veterinary Medical Diagnostic Laboratory, Columbia, MO USA
| | - Mahmoud Almasri
- University of Missouri–Columbia, Electrical Engineering and Computer Science, Columbia, MO USA
| |
Collapse
|
2
|
Devi S, Sharma N, Ahmed T, Huma ZI, Kour S, Sahoo B, Singh AK, Macesic N, Lee SJ, Gupta MK. Aptamer-based diagnostic and therapeutic approaches in animals: Current potential and challenges. Saudi J Biol Sci 2021; 28:5081-5093. [PMID: 34466086 PMCID: PMC8381015 DOI: 10.1016/j.sjbs.2021.05.031] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2020] [Revised: 05/11/2021] [Accepted: 05/12/2021] [Indexed: 01/19/2023] Open
Abstract
Fast and precise diagnosis of infectious and non-infectious animal diseases and their targeted treatments are of utmost importance for their clinical management. The existing biochemical, serological and molecular methods of disease diagnosis need improvement in their specificity, sensitivity and cost and, are generally not amenable for being used as points-of-care (POC) device. Further, with dramatic changes in environment and farm management practices, one should also arm ourselves and prepare for emerging and re-emerging animal diseases such as cancer, prion diseases, COVID-19, influenza etc. Aptamer – oligonucleotide or short peptides that can specifically bind to target molecules – have increasingly become popular in developing biosensors for sensitive detection of analytes, pathogens (bacteria, virus, fungus, prions), drug residues, toxins and, cancerous cells. They have also been proven successful in the cellular delivery of drugs and targeted therapy of infectious diseases and physiological disorders. However, the in vivo application of aptamer-mediated biosensing and therapy in animals has been limited. This paper reviews the existing reports on the application of aptamer-based biosensors and targeted therapy in animals. It also dissects the various modifications to aptamers that were found to be successful in in vivo application of the aptamers in diagnostics and therapeutics. Finally, it also highlights major challenges and future directions in the application of aptamers in the field of veterinary medicine.
Collapse
Affiliation(s)
- Sapna Devi
- Division of Veterinary Medicine, Faculty of Veterinary Sciences & A.H., Sher-e-Kashmir University of Agricultural Sciences & Technology of Jammu, R.S. Pura, Jammu, J & K, India
| | - Neelesh Sharma
- Division of Veterinary Medicine, Faculty of Veterinary Sciences & A.H., Sher-e-Kashmir University of Agricultural Sciences & Technology of Jammu, R.S. Pura, Jammu, J & K, India
- Corresponding author at: Division of Veterinary Medicine, Faculty of Veterinary Sciences & A.H., Sher-e-Kashmir University of Agricultural Sciences & Technology of Jammu, Jammu and Kashmir 181102, India.
| | - Touqeer Ahmed
- Division of Veterinary Medicine, Faculty of Veterinary Sciences & A.H., Sher-e-Kashmir University of Agricultural Sciences & Technology of Jammu, R.S. Pura, Jammu, J & K, India
| | - Zul I. Huma
- Division of Veterinary Medicine, Faculty of Veterinary Sciences & A.H., Sher-e-Kashmir University of Agricultural Sciences & Technology of Jammu, R.S. Pura, Jammu, J & K, India
| | - Savleen Kour
- Division of Veterinary Medicine, Faculty of Veterinary Sciences & A.H., Sher-e-Kashmir University of Agricultural Sciences & Technology of Jammu, R.S. Pura, Jammu, J & K, India
| | - Bijayalaxmi Sahoo
- Gene Manipulation Laboratory, Department of Biotechnology and Medical Engineering, National Institute of Technology Rourkela, Odisha, India
| | - Amit Kumar Singh
- Experimental Animal Facility, National JALMA Institute of Leprosy and Other Mycobacterial Diseases, Agra, U.P., India
| | - Nino Macesic
- Clinic for Reproduction and Theriogenology, Faculty of Veterinary Medicine, University of Zagreb, Zagreb, Croatia
| | - Sung Jin Lee
- College of Animal Life Sciences, Kangwon National University, Chuncheon, South Korea
| | - Mukesh Kumar Gupta
- Gene Manipulation Laboratory, Department of Biotechnology and Medical Engineering, National Institute of Technology Rourkela, Odisha, India
| |
Collapse
|
3
|
Bouvier-Müller A, Ducongé F. Nucleic acid aptamers for neurodegenerative diseases. Biochimie 2017; 145:73-83. [PMID: 29104136 DOI: 10.1016/j.biochi.2017.10.026] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Accepted: 10/31/2017] [Indexed: 02/07/2023]
Abstract
The increased incidence of neurodegenerative diseases represents a huge challenge for societies. These diseases are characterized by neuronal death and include several different pathologies, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease and transmissible spongiform encephalopathies. Most of these pathologies are often associated with the aggregation of misfolded proteins, such as amyloid-ß, tau, α-synuclein, huntingtin and prion proteins. However, the precise mechanisms that lead to neuronal dysfunction and death in these diseases remain poorly understood. Nucleic acid aptamers represent a new class of ligands that could be useful to better understand these diseases and develop better diagnosis and therapy. In this review, several of these aptamers are presented as well as their applications for neurodegenerative diseases.
Collapse
Affiliation(s)
- Alix Bouvier-Müller
- CEA, Fundamental Research Division (DRF), Institute of Biology François Jacob (Jacob), Molecular Imaging Research Center, 18 Route du Panorama, 92265 Fontenay-aux-Roses, France; Neurodegenerative Diseases Laboratory, CNRS CEA UMR 9199, Fontenay-aux-Roses, France; Paris-Saclay University, Paris-Sud University, Fontenay-aux-Roses, France
| | - Frédéric Ducongé
- CEA, Fundamental Research Division (DRF), Institute of Biology François Jacob (Jacob), Molecular Imaging Research Center, 18 Route du Panorama, 92265 Fontenay-aux-Roses, France; Neurodegenerative Diseases Laboratory, CNRS CEA UMR 9199, Fontenay-aux-Roses, France; Paris-Saclay University, Paris-Sud University, Fontenay-aux-Roses, France.
| |
Collapse
|
4
|
Ganesh HV, Chow AM, Kerman K. Recent advances in biosensors for neurodegenerative disease detection. Trends Analyt Chem 2016. [DOI: 10.1016/j.trac.2016.02.012] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
5
|
Aptamer-based 'point-of-care testing'. Biotechnol Adv 2016; 34:198-208. [PMID: 26876017 DOI: 10.1016/j.biotechadv.2016.02.003] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Revised: 02/06/2016] [Accepted: 02/07/2016] [Indexed: 12/13/2022]
Abstract
Aptamers are single-stranded oligonucleotides that can be artificially generated by a method called Systematic evolution of ligands by exponential enrichment (SELEX). The generated aptamers have been assessed for high-performance sensing applications due to their appealing characteristics. With either aptamers alone or complementing with antibodies, several high sensitive and portable sensors have been demonstrated for use in 'point-of-care testing'. Due to their high suitability and flexibility, aptamers are conjugated with nanostructures and utilized in field applications. Moreover, aptamers are more amenable to chemical modifications, making them capable of utilization with most developed sensors. In this overview, we discuss novel, portable, and aptamer-based sensing strategies that are suitable for 'point-of-care testing'.
Collapse
|
6
|
McConnell EM, Holahan MR, DeRosa MC. Aptamers as promising molecular recognition elements for diagnostics and therapeutics in the central nervous system. Nucleic Acid Ther 2015; 24:388-404. [PMID: 25296265 DOI: 10.1089/nat.2014.0492] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Oligonucleotide aptamers are short, synthetic, single-stranded DNA or RNA able to recognize and bind to a multitude of targets ranging from small molecules to cells. Aptamers have emerged as valuable tools for fundamental research, clinical diagnosis, and therapy. Due to their small size, strong target affinity, lack of immunogenicity, and ease of chemical modification, aptamers are an attractive alternative to other molecular recognition elements, such as antibodies. Although it is a challenging environment, the central nervous system and related molecular targets present an exciting potential area for aptamer research. Aptamers hold promise for targeted drug delivery, diagnostics, and therapeutics. Here we review recent advances in aptamer research for neurotransmitter and neurotoxin targets, demyelinating disease and spinal cord injury, cerebrovascular disorders, pathologies related to protein aggregation (Alzheimer's, Parkinson's, and prions), brain cancer (glioblastomas and gliomas), and regulation of receptor function. Challenges and limitations posed by the blood brain barrier are described. Future perspectives for the application of aptamers to the central nervous system are also discussed.
Collapse
Affiliation(s)
- Erin M McConnell
- 1 Department of Chemistry, Carleton University , Ottawa, Ontario, Canada
| | | | | |
Collapse
|
7
|
NAGAOKA T, TOKONAMI S, SHIIGI H, MATSUMOTO H, TAKAGI Y, TAKAHASHI Y. Development of an Electrochemical Cholesterol Sensor System for Food Analysis. ANAL SCI 2012; 28:187-91. [DOI: 10.2116/analsci.28.187] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Tsutomu NAGAOKA
- Department of Applied Chemistry, Graduate School of Engineering, Osaka Prefecture University
| | - Shiho TOKONAMI
- Nanoscience and Nanotechnology Research Center, Research Organization for the 21th Century, Osaka Prefecture University
| | - Hiroshi SHIIGI
- Department of Applied Chemistry, Graduate School of Engineering, Osaka Prefecture University
| | - Hiroaki MATSUMOTO
- Department of Applied Chemistry, Graduate School of Engineering, Osaka Prefecture University
| | | | | |
Collapse
|
8
|
Wang P, Hatcher KL, Bartz JC, Chen SG, Skinner P, Richt J, Liu H, Sreevatsan S. Selection and characterization of DNA aptamers against PrP(Sc). Exp Biol Med (Maywood) 2011; 236:466-76. [PMID: 21444369 DOI: 10.1258/ebm.2011.010323] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Transmissible spongiform encephalopathies (TSEs) are a group of zoonotic and fatal neurodegenerative disorders that affect humans and animals. The pathogenesis of TSEs involves a conformational conversion of the cellular prion protein (PrP) into abnormal isoforms. Currently, cellular and pathological forms of PrP are differentiated using specific antibody-based analyses that are resource intensive and not applicable to all species and strains. Thus, there is an urgent need for sensitive and efficient assays that can detect pathological forms of PrP. Using systematic evolution of ligands by exponential enrichment, we developed DNA aptamers that can differentiate normal and abnormal PrP isoforms. These aptamers represent the first reagents that can identify pathological isoforms of PrP across multiple host species. Second, they are able to distinguish different strains of prions. Third, they can be used to detect prions in peripheral blood cells, which are otherwise undetectable using conventional antibody-based detection methods. Thus, DNA aptamers offer promise for the development of presymptomatic screens of tissue, blood and other body fluids for prion contamination.
Collapse
Affiliation(s)
- Ping Wang
- Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA
| | | | | | | | | | | | | | | |
Collapse
|
9
|
AZAM MG, SHIBATA T, KABASHIMA T, KAI M. Sensitive Chemiluminescence Detection of Prion Protein on a Membrane by Using a Peroxidase-Labeled Dextran Probe. ANAL SCI 2011; 27:715. [DOI: 10.2116/analsci.27.715] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Md. Golam AZAM
- Faculty of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University
| | - Takayuki SHIBATA
- Faculty of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University
| | - Tsutomu KABASHIMA
- Faculty of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University
| | - Masaaki KAI
- Faculty of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University
- Global COE Program, Nagasaki University
| |
Collapse
|